Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abeona Therapeutics Inc (ABEO) vs Aehr Test Systems (AEHR) Price & Performance

Abeona Therapeutics IncTrade
Aehr Test SystemsTrade

Price performance (Past 24H)

Key statistics

Abeona Therapeutics Inc vs Aehr Test Systems — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $424.33M), while Aehr Test Systems trades at $119.99 (market cap $3.46B). The key difference: Aehr Test Systems is far larger — about 8.2× Abeona Therapeutics Inc's market cap. Which is the better fit depends on your goals.

ABEOAEHR
Market Cap
$424.33M$3.46B
Sector
HealthTechnology
52-Week High
$7.45$117.18
52-Week Low
$4.17$17.38
Enterprise Value
$279.23M$3.36B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abeona Therapeutics Inc

ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.

Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.

Aehr Test Systems

AEHR Test Systems trades at $103.07, up 3.34% with strong technical momentum and bullish moving average signals. The company shows improving earnings trends with three consecutive quarterly beats, though profitability remains negative with a -14.25% net margin. Recent news highlights significant silicon photonics orders and a strategic pivot toward AI infrastructure, driving investor optimism despite insider selling activity.

Outlook remains growth-focused with FY27 revenue guidance of 160-200% expansion, though high valuation (P/S 65.13) and customer concentration pose risks. Analyst consensus leans neutral with 33% buy ratings, while technical indicators suggest near-term support at $97 with resistance at $107. The stock's AI-driven backlog expansion supports bullish sentiment despite current negative cash flow.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abeona Therapeutics Inc

Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.

Read more on ABEO

About Aehr Test Systems

Aehr Test Systems provides testing and burn-in solutions for the semiconductor industry. Its systems ensure the reliability of AI processors, data center chips, and electric vehicle components at the wafer and package levels.

Read more on AEHR